

News Release

For Immediate Release

Contact: Nikki Panico Phone: (414) 389-4881

Web: www.komensoutheastwi.org

Email: nikkipanico@komensoutheastwi.org

Susan G. Komen® Welcomes New Members to National Board of Directors Five Leaders in International Business, Government Affairs, Law, Finance and Marketing Unanimously Elected, Expanding Komen Board of Directors

Fort Worth, TX — June 24, 2015 — Susan G. Komen, the world's largest breast cancer organization, welcomes five leaders in international business, government affairs, law, finance and marketing – and the organization's Affiliate Network – as new members of Komen's Board of Directors.

"We are thrilled with the depth of expertise and diversity of backgrounds that our new board members bring to our organization, and welcome them as leaders in our mission to end breast cancer, forever," said Linda P. Custard, Komen's Board Chairperson.

The new directors, elected unanimously on Wednesday, are:

Kaye Ceille, President of Zipcar, the world's largest car sharing service. Ceille brings nearly two decades of experience in senior leadership positions in the travel and transportation industry, including international operations, global partnerships and business development with Zipcar's parent, the Avis Budget Group. Ceille received a Bachelor of Business Administration degree from St. Norbert College in De Pere, Wisconsin, and an MBA from Loyola University in Chicago. Ceille is a cancer survivor who is active in cancer organizations.

Janet Dunn Frantz, a 14-year breast cancer survivor, joins the Komen Board as one of two board members nominated by Komen's Affiliate Network. Frantz previously served as Board President and Board Secretary of the Komen Virginia Blue Ridge Affiliate. She is an avid Komen supporter, participating in 3-Day walks and leading a top fundraising team in the Virginia Blue Ridge Komen Race for the Cure. Frantz has a background in commercial banking and spent her entire career with Bank of America and predecessor banks. Janet received a Bachelor of Arts in Economics from Wake Forest University.

Dan Glennon, Chief Operating Officer and Chief Financial Officer at SPANX. Prior to joining SPANX, Glennon held a number of strategic financial roles, including serving as Executive Vice President and Chief Financial Officer of Teavana, and most recently as the Chief Financial Officer of Larson-Juhl, a Berkshire-Hathaway subsidiary. Glennon earned his Bachelor of Business Administration degree from the University of Georgia and his MBA from Harvard.

Melissa Maxfield, Senior Vice President, Federal Government Affairs, for Comcast NBCUniversal. In this role, she was honored as one of MultiChannel News' Wonder Women for 2015 and named among the Most Powerful Women in Cable in 2012, 2013 and 2014 by CableFAX: The Magazine. Prior to joining Comcast in 2003, Maxfield served as the top staffer for Senate Majority Leader Tom Daschle (SD) and Senator Bob Kerrey (NE). She received her Bachelor's Degree in Political Science from Randolph-Macon Woman's College in Lynchburg, VA.

Meghan Shannon, shareholder in the business law practice at Reinhart Boerner Van Deuren s.c. in Milwaukee, Wisconsin. For the past six years, Shannon has been actively involved with the Komen Southeastern Wisconsin Affiliate, where she served as Board President and Treasurer. Shannon also was nominated through Komen's Affiliate Network and brings experience in many areas of corporate, business and finance law. She received her undergraduate degree in Accounting from the University of Notre Dame and her law degree from the University of Wisconsin law school. She is a certified public accountant.

Frantz and Shannon succeed Tricia Ory and Susie Knopf, whose terms have expired. Ceille, Glennon and Maxfield will fill three new board seats.

Since 1999, Komen Southeast Wisconsin has invested over \$10 Million into the local community. Komen Southeast Wisconsin has also invested over \$3.7 Million in national breast cancer research. Together with sister affiliates across the country, Susan G. Komen has invested \$840 million in breast cancer research through over 2400 research grants and 450 clinical trials.

###